Welcome to our dedicated page for PHAXIAM Therapeutics S.A. news (Ticker: PHXM), a resource for investors and traders seeking the latest updates and insights on PHAXIAM Therapeutics S.A. stock.
PHAXIAM Therapeutics S.A. (PHXM), founded in 2004, is a pioneering biopharmaceutical company dedicated to developing innovative therapies that address unmet medical needs, with a significant focus on cancer and orphan diseases. The company leverages its proprietary technology, which is centered on the encapsulation of therapeutic molecules into red blood cells. This encapsulation method presents multiple benefits over free-form compounds, such as minimizing the risk of allergic reactions and allowing the therapeutic substance to remain active in the body for an extended period.
PHAXIAM's flagship product targets relapsed and refractory acute lymphoblastic leukemia by depriving tumors of necessary nutrients. Having completed Phase III development, this product promises a groundbreaking therapeutic solution for patients with this challenging condition. The company's state-of-the-art production facility, located in Lyon, holds “pharmaceutical establishment” status, underscoring its commitment to high-quality manufacturing standards.
PHAXIAM has strategically partnered with Orphan Europe-Recordati (for distribution in Europe) and Teva (for distribution in Israel), enhancing its global reach and ensuring that its innovative therapies are accessible to a broader patient population. Recent developments include various investigator-initiated studies funded by hospital clinical research programs, reflecting the collaborative efforts to advance medical research and patient care.
The company recently reported its FY 2023 financial results and announced the effectiveness of the voluntary delisting of its American Depositary Shares from the NASDAQ Stock Market. PHAXIAM continues to engage with its stakeholders, providing regular updates through webinars and financial disclosures. For more detailed information, stakeholders are encouraged to visit the PHAXIAM website.
FAQ
What is the market cap of PHAXIAM Therapeutics S.A. (PHXM)?
What does PHAXIAM Therapeutics specialize in?
What is the core technology of PHAXIAM Therapeutics?
What is PHAXIAM's lead product?
Where is PHAXIAM's production facility located?
Who are PHAXIAM's distribution partners?
What recent financial updates has PHAXIAM provided?
How can I stay informed about PHAXIAM's latest developments?
What recent studies has PHAXIAM been involved in?
What are the benefits of PHAXIAM’s encapsulation technology?
Where can I find more information about PHAXIAM Therapeutics?
